NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.15 +0.17 (+2.44 %)
(As of 09/19/2018 03:00 AM ET)
Previous Close$6.98
Today's Range$6.90 - $7.19
52-Week Range$4.12 - $8.13
Volume349,600 shs
Average Volume919,751 shs
Market Capitalization$770.05 million
P/E Ratio-9.17
Dividend YieldN/A
Beta1.68
BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302

Debt

Debt-to-Equity Ratio0.35
Current Ratio1.25
Quick Ratio1.25

Price-To-Earnings

Trailing P/E Ratio-9.17
Forward P/E Ratio-8.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.19 million
Price / Sales31.05
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book8.41

Profitability

EPS (Most Recent Fiscal Year)($0.78)
Net Income$-65,780,000.00
Net Margins-270.95%
Return on Equity-107.85%
Return on Assets-47.69%

Miscellaneous

Employees85
Outstanding Shares109,380,000
Market Cap$770.05 million

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.05. The biotechnology company had revenue of $12.49 million for the quarter, compared to the consensus estimate of $3.80 million. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. View BioCryst Pharmaceuticals' Earnings History.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for BioCryst Pharmaceuticals.

What price target have analysts set for BCRX?

8 Wall Street analysts have issued twelve-month target prices for BioCryst Pharmaceuticals' shares. Their predictions range from $6.00 to $16.00. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $10.25 in the next year. This suggests a possible upside of 43.4% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.

What is the consensus analysts' recommendation for BioCryst Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (7/10/2018)
  • 2. HC Wainwright analysts commented, "NewCo Combines HAE Commercial & Deal-Making Expertise With Core Competency in Structure-Based Drug Design Diversification and management expertise drive the deal. Biocryst today announced its intention to merge with the oligomer company Idera (IDRA; Buy Rated) to form a NewCo that will continue to develop treatments for both HAE as well as checkpoint-refractory myeloma." (1/23/2018)

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 57)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 50)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 63)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 65)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 51)

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

News headlines about BCRX stock have trended somewhat positive this week, Accern reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for BioCryst Pharmaceuticals.

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (10.14%), BlackRock Inc. (7.09%), Jennison Associates LLC (3.51%), VHCP Management II LLC (2.25%), Millennium Management LLC (1.55%) and Northern Trust Corp (1.11%). Company insiders that own BioCryst Pharmaceuticals stock include Fred E Cohen, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Which institutional investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citadel Advisors LLC, Renaissance Technologies LLC, DAFNA Capital Management LLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Swiss National Bank and ClariVest Asset Management LLC. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Which institutional investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., VHCP Management II LLC, Bank of America Corp DE, Spark Investment Management LLC, State of Wisconsin Investment Board, Paloma Partners Management Co and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $7.15.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $770.05 million and generates $25.19 million in revenue each year. The biotechnology company earns $-65,780,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. BioCryst Pharmaceuticals employs 85 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]


MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  643
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel